Publicaciones en las que colabora con JUAN PASQUAU LIAÑO (102)

2024

  1. DOLAMA 200: Effectiveness and Safety of a Dual Therapy with Dolutegravir Plus Lamivudine in Treatment-Experienced HIV-1 Infected Real World Participants in Spain

    Viruses, Vol. 16, Núm. 2

  2. Dalbavancin real-life utilization among diabetic patients suffering from infections in Italy and Spain: The DALBADIA retrospective cohort study

    Journal of Global Antimicrobial Resistance, Vol. 36, pp. 200-209

2023

  1. EN-DALBACEN 2.0 Cohort: real-life study of dalbavancin as sequential/consolidation therapy in patients with infective endocarditis due to Gram-positive cocci

    International Journal of Antimicrobial Agents, Vol. 62, Núm. 3

  2. Expert Consensus: Main Risk Factors for Poor Prognosis in COVID-19 and the Implications for Targeted Measures against SARS-CoV-2

    Viruses, Vol. 15, Núm. 7

  3. Virologic Response to Dolutegravir Plus Lamivudine in People With Suppressed Human Immunodeficiency Virus Type 1 and Historical M184V/I: A Systematic Literature Review and Meta-analysis

    Open Forum Infectious Diseases, Vol. 10, Núm. 11

2022

  1. DOLAVI Real-Life Study of Dolutegravir Plus Lamivudine in Naive HIV-1 Patients (48 Weeks)

    Viruses, Vol. 14, Núm. 3

  2. Dalbavancin in clinical practice in Spain: A 2 year retrospective study

    JAC-Antimicrobial Resistance, Vol. 4, Núm. 6

  3. Incidence of nephrotoxicity associated with intravenous colistimethate sodium administration for the treatment of multidrug-resistant gram-negative bacterial infections

    Scientific Reports, Vol. 12, Núm. 1

  4. Rildo: Real-World Multicenter Study on the Effectiveness and Safety of Single-Tablet Regimen of Dolutegravir plus Rilpivirine in Treatment-Experienced People Living with HIV

    Viruses, Vol. 14, Núm. 12

  5. Timing in antibiotic therapy: when and how to start, de-escalate and stop antibiotic therapy. Proposals from a stablished antimicrobial stewardship program

    Revista Espanola de Quimioterapia, Vol. 35, pp. 102-107

2021

  1. Daptomycin Plus Fosfomycin Versus Daptomycin Alone for Methicillin-resistant Staphylococcus aureus Bacteremia and Endocarditis: A Randomized Clinical Trial

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Vol. 72, Núm. 9, pp. 1517-1525

  2. Effectiveness of the quadrivalent hpv vaccine in preventing anal ≥ hsils in a spanish population of hiv+ msm aged > 26 years

    Viruses, Vol. 13, Núm. 2

  3. Recommendations for antibiotic selection for severe nosocomial infections

    Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, Vol. 34, Núm. 5, pp. 511-524

  4. Risk factors for ≥high-grade anal intraepithelial lesions in MSM living with HIV and the response to topical and surgical treatments

    PLoS ONE, Vol. 16, Núm. 2 February

2020

  1. Addition of maraviroc versus placebo to standard antiretroviral therapy for initial treatment of advanced HIV infection: A randomized trial

    Annals of Internal Medicine, Vol. 172, Núm. 5, pp. 297-305

  2. Healthcare-associated pneumonia: a prospective study in Spain

    Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, Vol. 33, Núm. 5, pp. 358-368

  3. Primary resistance to integrase strand transfer inhibitors in Spain using ultrasensitive HIV-1 genotyping

    Journal of Antimicrobial Chemotherapy, Vol. 75, Núm. 12, pp. 3517-3524

  4. Safety and Tolerability of More than Six Days of Tedizolid Treatment

    Antimicrobial agents and chemotherapy, Vol. 64, Núm. 7

  5. Virological outcome among HIV infected patients transferred from pediatric care to adult units in Madrid, Spain (1997–2017)

    Scientific Reports, Vol. 10, Núm. 1

2019

  1. ART is key to clearing oncogenic HPV genotypes (HR-HPV) in anal mucosa of HIV-positive MSM

    PLoS ONE, Vol. 14, Núm. 10